Perspective Therapeutics Inc.
CATX | AMEX
$2.90
-$0.07 (-2.36%)
Sep 22, 2026, 10:40 AM ET · Market open
Company Profile
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Key Executives
| Name | Position |
|---|---|
| Johan Spoor | Chief Executive Officer & Director |
| Amos Hedt PGradDip | Chief Business Strategy Officer |
| Andrew Bright | Executive Vice President of Brachytherapy |
| Annie J. Cheng | Vice President of Investor Relations |
| Chris Nenno | General Counsel & Corporate Secretary |
| Joel David Sendek | CFO & Principal Financial Officer |
| Jonathan R. Hunt | Chief Accounting Officer |
| Markus Puhlmann | Chief Medical Officer |
| Michael K. Schultz | Co-Founder & Senior Scientific Advisor |
| Paul Lyne | Chief Science Officer |
| Shane Cobb | Executive Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 04, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Sep 04, 2026 | SC 13D/A | [Amend] Filing |
| Sep 03, 2026 | 4 | Filing |
| Sep 02, 2026 | 4 | Filing |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 10, 2026 | 10-Q | Quarterly Report |
| Aug 10, 2026 | 8-K | Current Report |
| Aug 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 03, 2026 | 8-K | Current Report |
Perspective Therapeutics Inc.
| Country | United States |
| IPO Date | Nov 9, 2005 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 165 |
| CEO | Johan Spoor |
Contact Details
2401 Elliott Avenue Seattle,
Washington 98121 United States
Stock Details
| Ticker Symbol | CATX |
| Exchange | AMEX |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0000728387 |
| CUSIP Number | 46489V302 |
| ISIN Number | US46489V3024 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove CATX